GtoPdb Ligand ID: 7242

Synonyms: CL-232315 | Novantrone®
mitoxantrone is an approved drug (FDA (1987))
Compound class: Synthetic organic
Comment: Marketed formulations may contain mitoxantrone hydrochloride (PubChem CID 5458171).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: mitoxantrone

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 8
Rotatable bonds 12
Topological polar surface area 163.18
Molecular weight 444.2
XLogP -0.6
No. Lipinski's rules broken 2
Canonical SMILES OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)c(O)ccc1O)NCCNCCO
Isomeric SMILES OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)c(O)ccc1O)NCCNCCO
InChI InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
No information available.
Summary of Clinical Use
Used to treat prostate cancer, metastatic breast cancer, some leukemias and to relieve the symptoms of relapsing multiple sclerosis.
Mechanism Of Action and Pharmacodynamic Effects
Mitoxantrone causes cross-links and strand breaks in DNA, interferes with RNA, and inhibits topoisomerase II. The result of these effects is cell death. See the DrugBank link for further details.
External links